autologous cultured chondrocytes on porcine collagen membrane

BIOLOGICAL3 trials

Sponsors

Vericel Corporation

Conditions

Articular Cartilage DefectArticular Cartilage DefectsChondral Defect

Phase 3

Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee

CompletedNCT00719576

Vericel CorporationArticular Cartilage Defect

Start: 2008-07-31End: 2012-03-31Updated: 2021-05-12

A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle

RecruitingNCT06915233

Vericel CorporationArticular Cartilage Defect, Chondral Defect

Start: 2026-03-01End: 2030-07-01Target: 309Updated: 2026-03-06

Unknown Phase

Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee

CompletedNCT01251588

Vericel CorporationArticular Cartilage Defects

Start: 2010-12-31End: 2015-03-31Updated: 2021-05-12